The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy

@inproceedings{Paolicelli2016TheCO,
  title={The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy},
  author={Damiano Paolicelli and Sergio Iannazzo and Laura Santoni and Antonio Iaffaldano and Valentina Di Lecce and Alessia Manni and Vito Lavolpe and Carla Tortorella and Mariangela D'Onghia and Vita Direnzo and Elisa Puma and Maria Trojano},
  booktitle={PloS one},
  year={2016}
}
BACKGROUND Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE The aim of this study was to estimate the cost of RRMS patients who… CONTINUE READING
  • Blog articles referencing this paper

  • Presentations referencing similar topics